Homophilic antibodies have greater targeting and effector potency than nonhomophilic antibodies. Homophilic antibodies have been tested in vitro and in animal models to demonstrate their superior ...

VYD2311 showed a 17-fold higher potency than pemivibart in in vitro ... an ongoing Phase 1/2 trial of VYD2311, a monoclonal antibody (mAb) candidate. A formal estimate of in vivo half-life is ...

By engineering the 10E8 antibody, NIAID scientists have improved the properties of 10E8 that affect manufacturability, such as solubility, while preserving its neutralizing breadth and potency.